相关实验视频

Updated: Feb 26, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

使用基于结构的集成对接研究和功能验证发现了一种新的VEGFR2抑制剂:在向癌症治疗中潜在的应用

Hussam Albassam¹, Saad Alobid², Faris Almutairi²

¹Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, PO Box 2457, Riyadh, 11451, Kingdom of Saudi Arabia. halbassam@ksu.edu.sa.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

|February 24, 2026

概括

研究人员发现了一种新型化合物,可以抑制血管内皮生长因子受体2 (VEGFR2),这是癌症的关键标. 这种潜在的抗癌药物在减少瘤生长方面表现有前途,因此需要进一步开发.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

癌症是全球主要的死亡原因,目前的治疗方法面临药物耐药性和副作用等挑战.
血管内皮生长因子受体2 (VEGFR2) 对于瘤血管生成至关重要,使其成为一个有前途的治疗点.
开发新的VEGFR2抑制剂对于推进抗血管性癌症疗法至关重要.

研究的目的:

通过综合计算和实验方法识别血管内皮生长因子受体2 (VEGFR2) 的新型抑制剂.
评估潜在的VEGFR2抑制剂的抗增殖和激酶抑制活性.
发现一种主要化合物,用于开发新的抗血管新生和抗癌药物.

主要方法:

使用基于结构的分子对接与VEGFR2晶体结构对比,选了超过2000个化合物的库.
进行了详细的结合相互作用分析和重制模拟,以探索连接体结合模式.
对VEGFR2-过度表达U87细胞进行了细胞毒性测定和酶性测定,以确认VEGFR2激酶抑制.

主要成果:

在VEGFR2-过度表达U87细胞中发现了几种具有显著抗繁殖作用的高级化合物.
证实了一种新型化合物的强烈VEGFR2激酶抑制活性.
详细的结合相互作用揭示了化合物的抑制机制.

结论:

一种新型化合物已被确定为VEGFR2.2的强有力的抑制剂.
这种化合物显示出作为抗血管和抗癌治疗剂的潜力.
这种化合物的进一步优化对于临床开发是有必要的.

关键词:

癌症药物发现的发现基于结构的对接研究.有针对性的癌症治疗.这是一种VEGFR2抑制剂.在VEGFR2信号通路中,

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...